Xcout IntelD&D Pharmatech
D&D Pharmatech Inc. is a clinical-stage biotechnology company specializing in the development of GLP-1 receptor agonists and proprietary peptide technologies.
Subscribe to see D&D Pharmatech’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
D&D Pharmatech at a glance
D&D Pharmatech is a biotechnology company headquartered in South Korea. Its most recent funding round raised $10.8M in June 2025. Xcout tracks 13 named people at D&D Pharmatech, including Seulki Lee (Chief Executive Officer).
D&D Pharmatech leadership
- Seulki LeeChief Executive Officer
- 홍성훈최고재무책임자 (CFO)
- Yen-Huei Lin최고기술 및 생산 책임자 (CTMO)
- 이슬기대표이사 (CEO) / 디앤디파마텍, Neuraly
- Martin G. Pomper창업자 및 前 CSO / Precision Molecular (現 Neuraly)
- Ted Dawson창업자 / Valted Seq
7 more named people on record for D&D Pharmatech, with roles, board committees and tenure — see the full roster →
D&D Pharmatech funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $10.8M | — | |
| — | $51M | 9 named | |
| — | $137.1M | 6 named | |
| — | $16.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
D&D Pharmatech competitors
A few of D&D Pharmatech's closest competitors — see the full list of competitors and alternatives →
Parabolica Therapeutics develops proprietary peptide conjugation technologies focused on obesity and other metabolic conditions. The company researches and advances therapeutic programs through its scientific approach.
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
Inversago Pharma is a Canadian biotechnology company developing peripherally restricted CB1 receptor antagonists/inverse agonists for metabolic, fibrotic, and related diseases. Its drug-development programs are intended to serve patients with conditions such as obesity, metabolic syndrome, and diabetic kidney disease.
Imagine Pharma LLC is a biotechnology company that develops novel polypeptide-based platforms focused on oral delivery for biologic drugs, therapeutics for various disease states, and regenerative medicine. The company aims to create first-in-class treatments for conditions such as diabetes and wound healing, alongside offering oral peptide dietary supplements and functional ingredients for consumers.
Xianweida Biotech is a biopharmaceutical company focused on the research, development, and manufacturing of advanced weight management therapies and innovative treatments addressing urgent medical needs. The company is nearing commercialization and has partnered with Pfizer China for its GLP-1 drug portfolio.
Get D&D Pharmatech's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on D&D Pharmatech in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access